Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection
Rattachement africain : ir. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: With the emergence of the coronavirus disease 2019 (COVID-19) and inability of healthcare systems to control the disease, various therapeutic theories with controversial responses have been proposed. Plasmapheresis was administered as a medication. However, the knowledge of its efficacy and indications is inadequate. This study evaluated the use of plasmapheresis in critically ill patients with cancer. Methods: This randomized clinical trial was conducted on 86 patients with malignancies, including a control group (N=41) and an intervention group (N=45) with severe COVID-19 during 2020-21. Both groups were treated with routine medications for COVID-19 management according to national guidelines, and plasmapheresis was applied to the intervention group. C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase, hemoglobin, and white blood cell, polymorphonuclear, lymphocyte, and platelet levels were measured at admission and at the end of plasmapheresis. Other variables included neutrophil recovery, intensive care unit admission, intubation requirements, length of hospital stay, and hospitalization outcomes. Results: <0.001). Conclusion: Based on the study findings, plasmapheresis led to a significant improvement in laboratory markers and survival rate in patients with severe COVID-19. These findings reinforce the value of plasmapheresis in cancer patients as a critical population suffering from neutropenia and insufficient immune responses.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection
- Date Crossref
- 10/05/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Isfahan pays non établi dans la noticeUniversité ou école supérieure
-
Isfahan Fertility and Infertility Center pays non établi dans la noticeStructure de recherche
-
Isfahan University of Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Infectious Diseases and Tropical Medicine Research Center pays non établi dans la noticeStructure de recherche
-
Child Growth and Development Research Center pays non établi dans la noticeStructure de recherche
-
Cancer Prevention Research Center Seyed Al-Shohada Hospital pays non établi dans la noticeStructure de recherche
-
Mycology Reference Laboratory pays non établi dans la noticeStructure de recherche
-
Acquired Immunodeficiency Research Center pays non établi dans la noticeStructure de recherche
University of Isfahan, Isfahan Fertility and Infertility Center et Isfahan University of Medical Sciences, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.